# Adversarial verification verdict — bap1_tumour_predisposition_syndrome

## 1. DOSE LEAK
None. Grepped for mg / mg-m2 / AUC / numbered cycle-day schedules and scanned every raw digit in
the file (43 = chapter number, 12 = "12th ed", stray "1"s = markdown list numbers / line 116
reference). No drug dose, mg/m2, AUC, or numbered administration schedule appears anywhere in the
sidecar.

## 2. UNGROUNDED CLAIMS
None found that are presented as DeVita-sourced without support, and none of the non-DeVita content
is a fabricated/specific regimen-trial-statistic — everything outside the DeVita-grounded core is
generic, guideline-standard practice and is explicitly labeled inline as
"(general oncology standard, not from DeVita's section on this disease)". Specific notes:
- Core DeVita claims (BAP1 as inherited clear-cell RCC/uveal-melanoma/cutaneous-melanoma/mesothelioma
  syndrome, two-hit LOH tumor-suppressor mechanism, early-onset aggressive RCC with poor survival, no
  dedicated BAP1-RCC trials, COMPARZ-cohort finding that BAP1 mutation carriers on VEGF-targeted
  therapy had reduced PFS/OS) all verified verbatim against DeVita 12th ed, Ch. 43 (lines
  ~149598–149746, incl. Table 43.4). Trial name "COMPARZ" and citation are correct and unique in the
  source text.
- The mesothelioma "younger age, less asbestos exposure, more indolent/better-survival course" claim
  is NOT in Ch. 43's BAP1 section but IS independently corroborated in DeVita Ch. 76
  ("BAP1 Germline Mutations and Survival," lines ~291897–292020: sevenfold/5-10-year improved
  survival, less asbestos exposure, younger than expected, well-differentiated tumors). The sidecar
  correctly declines to cite this as coming from "this disease's section" and labels it general
  knowledge instead — appropriately conservative, not a fabrication, arguably under-cites available
  support.
- "Peritoneal predominance" of BAP1-mesothelioma and organ-specific surveillance schedules
  (ophthalmology exam cadence, skin exam cadence, imaging cadence) are standard-of-care statements
  with no DeVita citation found for this specific disease's section — correctly flagged as general
  oncology standard, not attributed to DeVita.
- "Antifolate-platinum doublet ± anti-angiogenic" for advanced mesothelioma is drug-class language
  (no specific drug names/doses), uncontroversial standard of care, correctly flagged as general
  standard not DeVita-sourced.
- No invented trial names, no invented statistics, no specific regimen beyond drug-class level
  anywhere in the document.

## 3. CITATION
Present: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th
ed." (line 116) — name only, no page numbers. Correct.

## 4. VERDICT: CLEAN (ready for R1)

No dose leaks, no fabricated regimens/trials/statistics, DeVita-sourced claims verified against the
source text, and every claim beyond DeVita's specific disease section is honestly labeled as general
oncology standard rather than misattributed to DeVita.
